College of Pharmacy alumna Ivy Ton, COP ‘22, and colleagues, performed a cross-sectional study of 19 publicly available low-cost generic program (LCGP) drugs, in March and April 2023 in the U.S. within a clinical framework for 6 cardiovascular diseases. The findings were that coverage of evidence-based medicines varied by LCPG and condition.
“Medication coverage in LCGPs varies widely for core, evidence-based CVD medications in all CVD conditions investigated, with differences in medication coverage options and strengths by program and condition,” the authors write. “Health care professionals should consider medication availability and LCGP-specific characteristics when recommending their use.”
The study was published online in the Annals of Internal Medicine and can be viewed here: https://www.acpjournals.org/doi/10.7326/M23-0287.
(Image: LinkedIn)